share_log
Benzinga ·  May 1 08:11
Denali Therapeutics Completes Enrollment for Regimen G Evaluating EIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment